Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 8, 2006

Biovitrum to Improve Manufacturing Process for Protein-based Allergy Candidate

  • Biovitrum will develop and manufature Resistentia Pharmaceuticals’ new protein-based allergy drug, RES 08, for use in Phase III trials, under an agreement between the companies.

    Biovitrum will expand on the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the high demands of a Phase III trial and manufacture sufficient amounts of the drug for the trial. The project will run for more than two years beginning in November.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »